RxDoctor Payments Data

Garrett Bond

Acute Care · Hattiesburg, MSNPI 1326620220

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 124 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 23 manufacturers reported payments, led by Boston Scientific at 45.7% of the total. 2025 is the largest year on record at $796, more than ten times the $51 reported in 2022.

$2,159in general payments, 2019–2025

Across 124 payments — averaging $17.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$986
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$290
  • Novartis$121
  • Philips North America LLC$103
  • Stryker$96
  • Cardiva Medical, Inc.$79
  • plus $485 from 17 others

What the payments were for

  • Food & beverage$2,159100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,159 in reported general payments places this provider in the 75th percentile of 223 acute care providers in Mississippi.

See all acute care providers in Mississippi

Medicare billing

Part B allowed, 2024
$17,853
Medicare patients
147
Services billed
269

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban71$42,112
EntrestoSacubitril/Valsartan34$17,820
JardianceEmpagliflozin12$6,974
Isosorbide Dinitrate12$523
ClopidogrelClopidogrel Bisulfate66$389
Potassium Chloride41$291
SotalolSotalol Hcl23$254
Amiodarone Hcl16$240
Atorvastatin Calcium42$186
Pantoprazole Sodium36$185
Carvedilol30$154
Bumetanide11$139
Metoprolol Succinate28$136
Metoprolol Tartrate38$130
Losartan Potassium35$129

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$17$42,11271 claims
NovartisEntresto$121$17,82034 claims
Boehringer IngelheimJardiance$34$6,97412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 223 acute care providers in Mississippi.

Other acute care in Hattiesburg

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →